Press release
Non-Hodgkin Lymphoma Pipeline Appears Robust With 180+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Non-Hodgkin Lymphoma Treatment Landscape. Click here to read more @ Non-Hodgkin Lymphoma Pipeline Outlook [https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Non-Hodgkin Lymphoma Pipeline Report
* In June 2025, AstraZeneca announced a study is designed to evaluate the safety, tolerability, PK, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
* In June 2025, Genmab conducted a study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed.
* In June 2025, Artiva Biotherapeutics Inc. organized clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituximab (including the DLBCL specific cohort) or in combination with bendamustine and rituximab; 2) to evaluate the potential clinical activity of AB-101 when given in combination with rituximab or in combination with bendamustine and rituximab (combination cohorts only); and 3) to identify the recommended Phase 2 dose (RP2D). The primary objective of Phase 2 is to determine whether AB-101 in combination with rituximab or in combination with bendamustine and rituximab has anti-cancer activity in patients.
* DelveInsight's Non-Hodgkin Lymphoma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Non-Hodgkin Lymphoma treatment.
* The leading Non-Hodgkin Lymphoma Companies such as Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA and others.
* Promising Non-Hodgkin Lymphoma Pipeline Therapies such as Bendamustine hydrochloride injection, Glofitamab, Atezolizumab, Obinutuzumab, Lenalidomide, Velcade, Temsirolimus, PF-3512676 and others.
Discover groundbreaking developments in Non-Hodgkin Lymphoma Therapies! Gain in-depth knowledge of key Non-Hodgkin Lymphoma clinical trials, emerging drugs, and market opportunities @ Non-Hodgkin Lymphoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Non-Hodgkin Lymphoma Emerging Drugs Profile
* Golcadomide: Bristol Myers Squibb
Golcadomide is a novel cereblon E3 ligase modulator (CELMoD) being investigated for the treatment of aggressive B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). In combination with R-CHOP chemotherapy, it has shown promising antitumor activity in high-risk DLBCL patients, with a high overall response rate (ORR) and complete metabolic response (CMR). Currently, the drug is in Phase III stage of its clinical trial for the treatment of Non-Hodgkin Lymphoma.
* MEN 1703: Ryvu Therapeutics
MEN1703 (SEL24) is a clinical-stage program discovered and developed by Ryvu Therapeutics and licensed to the Menarini Group. MEN1703 is a first-in-class, dual PIM/FLT3 kinase inhibitor with a unique activity profile. By design, this profile may provide responses to treatment that are more durable than current options and address a disease that has progressed following FLT3 inhibition. Preclinical data suggests therapeutic potential in both hematological malignancies and in solid tumors. Ryvu has granted the Menarini Group an exclusive worldwide license to further research, develop, manufacture and commercialize MEN1703 (SEL24). Currently the drug is in Phase II stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma.
* LP-168: Guangzhou Lupeng Pharmaceutical
LP-168 is a third-generation, orally active, irreversible EGFR tyrosine kinase inhibitor (TKI) developed by Guangzhou Lupeng Pharmaceutical for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, including T790M resistance mutations. It is designed to target mutant EGFR while sparing wild-type EGFR, potentially reducing side effects. LP-168 has shown promising preclinical activity and is currently in clinical trials. The company is exploring its use in both first-line and resistant EGFR-mutant NSCLC settings. Currently the drug is in Phase II stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma.
* DR-0201: Dren Bio
DR-0201 is an investigational drug developed by D.R. Pharmatech, designed as a novel anti-cancer agent targeting HER2-expressing tumors, particularly in gastric and breast cancers. It is a HER2-targeting antibody-drug conjugate (ADC) that combines a monoclonal antibody with a cytotoxic payload to selectively kill cancer cells while minimizing damage to healthy tissue. DR-0201 aims to overcome resistance seen with existing HER2 therapies. The product is currently undergoing preclinical or early-phase clinical evaluation. Currently the drug is in Phase I stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma.
* ETR-7072: EntreChem
ETR-7072 is an investigational small-molecule drug developed by EntreChem, designed to target cancer by modulating transcriptional programs involved in tumor growth and survival. It is part of EntreChem's novel class of natural product-inspired compounds with multi-targeted activity, potentially affecting epigenetic regulators and oncogenic pathways. ETR-7072 shows promise in preclinical models for treating aggressive and resistant cancers. The compound is currently in early-stage development, with ongoing studies to assess its safety and efficacy. Currently the drug is in Preclinical stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma.
The Non-Hodgkin Lymphoma Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Hodgkin Lymphoma Treatment.
* Non-Hodgkin Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Hodgkin Lymphoma market
Stay informed about the Non-Hodgkin Lymphoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Non-Hodgkin Lymphoma Unmet Needs [https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Non-Hodgkin Lymphoma Companies
Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA and others.
Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Transform your understanding of the Non-Hodgkin Lymphoma Pipeline! See the latest progress in drug development and clinical research @ Non-Hodgkin Lymphoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Non-Hodgkin Lymphoma Pipeline Report
* Coverage- Global
* Non-Hodgkin Lymphoma Companies- Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA and others.
* Non-Hodgkin Lymphoma Pipeline Therapies- Bendamustine hydrochloride injection, Glofitamab, Atezolizumab, Obinutuzumab, Lenalidomide, Velcade, Temsirolimus, PF-3512676 and others.
* Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Research-Access the Full Non-Hodgkin Lymphoma Pipeline Analysis Today! @ Non-Hodgkin Lymphoma Drugs and Companies [https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Non-Hodgkin Lymphoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Non-Hodgkin Lymphoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Golcadomide: Bristol Myers Squibb
* Mid Stage Products (Phase II)
* MEN 1703: Ryvu Therapeutics
* Early Stage Products (Phase I)
* DR-0201: Dren Bio
* Preclinical and Discovery Stage Products
* ETR-7072: EntreChem
* Inactive Products
* Non-Hodgkin Lymphoma Key Companies
* Non-Hodgkin Lymphoma Key Products
* Non-Hodgkin Lymphoma- Unmet Needs
* Non-Hodgkin Lymphoma- Market Drivers and Barriers
* Non-Hodgkin Lymphoma- Future Perspectives and Conclusion
* Non-Hodgkin Lymphoma Analyst Views
* Non-Hodgkin Lymphoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nonhodgkin-lymphoma-pipeline-appears-robust-with-180-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-nhl-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Hodgkin Lymphoma Pipeline Appears Robust With 180+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4088537 • Views: …
More Releases from ABNewswire
Understanding Magnetic Switches: Types, Working Principles, and Applications
A magnetic switch is a versatile electrical device that operates by responding to magnetic fields. From Hall Effect to reed switches, explore their functions, types, and diverse applications.
What is a Magnetic Switch?
A magnetic switch is an electrical device that operates by responding to the presence of a magnetic field. It functions by closing or opening its contacts based on the strength of the magnetic field. Specifically, the switch remains closed…
Innovating embedded downlight technology: Leading the global trend of intelligen …
The strong rise of China's manufacturing industry has profoundly reshaped the technological landscape and development trajectory of embedded downlights. With its unparalleled industrial chain advantages, continuous technological innovation, and significant cost-effectiveness, Chinese enterprises have risen from participants in the global lighting industry to undisputed leaders. This transformation goes far beyond the huge production scale; it lies in the thorough innovation of the core technical content and application boundaries of embedded…
North China Electric Power University Foreign Aid Training Program Visits Yiyuan …
On July 23, 2025, the Electrical Industry Training Program of North China Electric Power University's Foreign Aid Project visited Yiyuan Technology for an exchange visit. The purpose was to gain in-depth insights into the company's innovations in renewable energy technology promotion and application [https://www.yiyen.com/about/], and to build bridges connecting university-enterprise cooperation with foreign aid initiatives.
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-1.jpg
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-3.jpg
Upon arrival, the delegation received a warm welcome from company leadership and the reception…
Pure Sine Wave Low Frequency Inverter Charger
Pure sine wave low frequency inverter [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] is widely used and suitable for a variety of scenarios. In terms of home backup power, it can provide reliable power during power outages, ensuring that essential appliances such as refrigerators, air conditioners and medical equipment continue to operate . For solar power generation systems, Inverter charger [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] can converter DC Power from Battery, which charged by solar panels, into clean alternating current…
More Releases for Lymphoma
Lymphoma Treatment Market - Liberating Lives from Lymphoma: State-of-the-Art Tre …
Newark, New Castle, USA: The "Lymphoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Lymphoma Treatment Market: https://www.growthplusreports.com/report/lymphoma-treatment-market/8879
This latest report researches the industry structure, sales, revenue,…
Lymphoma Treatment Market - Inspiring Resilience, Shaping Survival: Innovations …
Newark, New Castle, USA - new report, titled Lymphoma Treatment Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Lymphoma Treatment market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Lymphoma Treatment market. The report offers an overview of the market, which…
Lymphoma Therapeutics Market: New Frontiers in Lymphoma Therapeutics | By AMR
Allied Market Research recently said Lymphoma is a type of cancer that affects the lymphatic system, which is an integral part of the body's immune system. While chemotherapy and radiation therapy have been the standard treatment options for lymphoma, recent advances in research have led to the development of new targeted therapies and immunotherapies.
♦ 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.alliedmarketresearch.com/request-toc-and-sample/1448
One such targeted therapy is monoclonal antibodies, which can specifically target…
Daratumumab Market Precise Analysis , Forecast || key Players- Multiple Myeloma, …
Looking at the current market trends as well as the promising demand status of the “Daratumumab Market”, it can be projected that the future years will bring out positive outcomes. This research report added by Market Research Hub (MRH) on its online portal delivers clear insight about the changing tendencies across the global market. Readers can gather prime facets connected to the target market which includes product, end-use and application;…
T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. T-Cell Lymphoma Market Analysis
2. Mechanism of T-Cell Lymphoma Therapeutics
3. T-Cell Lymphoma Drug Market Overview
3.1 Current Market Scenario
3.2 T Cell Lymphoma Clinical Pipeline Overview
4. T-Cell Lymphoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. T-Cell Lymphoma Drug Market Future Prospects
6. T-Cell Lymphoma Drug Clinical Pipeline By Company…
B Cell Lymphoma Market B Cell Lymphoma Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to B Cell Lymphoma
1.1 Outline
1.1.1 Non-Hodgkin’s Lymphoma
1.1.2 Hodgkin’s Lymphoma
1.2 Classification of the B Cell lymphoma
1.2.1 Diffuse Large B Cell Lymphoma
1.2.2 Follicular Lymphoma
1.2.3 Mantle Cell Lymphoma
1.2.4 Burkitt Lymphoma
1.3 Stages of…
